


1/5

Applicant: Nagy  
Filing Date: September 10, 2003  
Application No.: 10/659,578  
Attorney Docket No.: BWT-003US  
Express Mail Label No.: EV669115945US  
REPLACEMENT SHEET 1 OF 5

Figure 1. Flow cytometer readouts from a control subject, preAD subject and AD patient.



BEST AVAILABLE COPY

Figure 2. Relative and age-corrected relative lengthening of the G1 phase under the influence of Rapamycin.





Figure 3. Effects of 24 hours rapamycin treatment on cell survival.



3/5

Figure 4. Effects of doxorubicine treatment on cell survival




Figure 5. Effects of  $H_2O_2$  treatment on cell survival




Figure 6. PCR-SSCP analysis for p21 exon2, p57 exon 2 fragments 2A and 2B




Figure 7. Relationship between p21 variants A and B and cyclin expression in the brain.




Figure 8. Relationship between p57 exon 2A variants A and B and cyclin expression in the brain in patients with normal p21 (allele B).




Figure 9. The prevalence of somatic mutations in relation to AD progression and cell cycle proteins in the brain.

